P hysiology-guided coronary revascularization is currently recommended in clinical practice guidelines on the grounds of ample evidence supporting its clinical value (1). Compared with angiography alone, decision making using fractional flow reserve (FFR) improves patient outcomes and procedural cost efficiencies (2) . These benefits are due largely to deferral of myocardial revascularization in hemodynamically nonsignificant stenosis (3) (4) (5) . instantaneous wave-free ratio (iFR)-based revascularization, the latter a novel adenosine-free index of stenosis severity (6, 7) . The combined dataset of both studies provides a unique opportunity to revisit the safety of physiology-guided deferral of revascularization in contemporary clinical practice, with the added value of depicting the predominant clinical use of FFR, which is interrogation of stenoses with intermediate angiographic severity (8) (9) (10) .
In this study, we investigated the 1-year clinical outcomes of patients who were included in the per- In both trials, all participants provided written informed consent before enrollment.
PROCEDURE. Physiological measurements were performed in the usual manner using the same coronary pressure guidewire (Verrata, Philips Volcano, San Diego, California). Before measurement, intracoronary nitrates were administered to control vasomotor tone. Pre-specified treatment thresholds were 0.89 for iFR and 0.80 for FFR. Stenoses were revascularized with either PCI or coronary artery bypass grafting. When iFR or FFR exceeded these prespecified thresholds, treatment was deferred. Pressure drift was assessed using the pressure ratio at the catheter tip after each physiological measurement. Pooled Analysis of DEFINE-FLAIR and iFR-SWEDEHEART If the pressure ratio exceeded AE0.02, physiological measurements were repeated. For patients assigned to FFR, hyperemia was obtained with intravenous or intracoronary hyperemic agents as previously described (6, 7) . When multivessel revascularization was required, investigators could stage procedures within 60 days of the index measurement. Revascularization was performed according to standard clinical practice, with pharmacological therapy left to the discretion of the treating physician. Results are reported using hazard ratios (HRs), 95% 2-sided confidence intervals (CIs), and cumulative hazard curves. Analyses were performed in an unadjusted manner as well as adjusted for the following baseline characteristics that were chosen a priori for their known associations with cardiovascular events: age, sex, body mass index, clinical presentation, Canadian Cardiovascular Society class for grading of angina pectoris, diabetes, hypertension, hyperlipidemia, smoking status, previous MI, and previous PCI.
Fully adjusted results are presented in the text and both unadjusted and fully adjusted in the tables. Values are mean AE SD or % (n). When the deferred population was stratified according to clinical presentation, overall less lesions were deferred in ACS compared with clinical presentation with SAP (36% vs. 50%; p < 0.001). In SAP, more lesions were deferred with iFR than FFR (55% vs. 48%; p < 0.001). In ACS, deferral rates were similar for both iFR and FFR guidance (36% vs. 36%; p ¼ 0.91). When stratified according to clinical presentation, the overall MACE rate in patients with ACS (7.7%) was higher than in patients with SAP (6.0%) (fully adjusted HR: 0.72 in favor of SAP; 95% CI: 0.55 to 0.93; p ¼ 0.01) (Online Table 3 ). In the deferred population, this difference was driven mainly by a higher Table 3 ).
RESULTS
In the deferred population, at 1 year, the primary endpoint occurred in 46 of 1,117 patients (4.12%) in the iFR group and in 41 of 1,013 patients (4.05%) in the FFR group (fully adjusted HR: 1.13; 95% CI: 0.72 to 1.79; p ¼ 0.60) ( Figure 3) . The HRs for the individual components of MACE for iFR-versus FFR-guided deferral are displayed in Table 4 . Unplanned revascularization was the biggest contributor numerically to the total MACE rate for both iFR-and FFR-deferred groups (2.78% and 3.26%, respectively; p ¼ 0.63).
There were no significant differences in the components of MACE between the 2 physiological techniques.
Within the deferred group, the MACE rate was more influenced by clinical presentation in patients evaluated with FFR (unadjusted HR: 0.52 in favor of SAP; 95% CI: 0.27 to 1.00; p < 0.05) than in those evaluated with iFR (unadjusted HR: 0.74 in favor of SAP; 95% CI: 0.38 to 1.43; p ¼ 0.37) ( Table 5) , with a statistically nonsignificant interaction (Figure 4) . The effect of clinical presentation on MI rate was more Values are % (n) or mean AE SD, unless otherwise indicated. Table 1 . Values are % (n), unless otherwise indicated. Tables 1 and 3 . Values are % (n), unless otherwise indicated. Tables 1 and 3 . The present analysis confirms that among patients who had revascularization deferred, those presenting with ACS had a higher 1-year MACE rate than those presenting with SAP (5.91% vs. 3.64%;
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fully adjusted HR: 0.61; 95% CI: 0.38 to 0.99; p ¼ 0.04) ( Table 3 ). These findings are in agreement with recently reported studies (13, 14) . Hakeem et al. (14) found that FFR-based deferral of PCI in patients with ACS was associated with a more than 2-fold increase in the combined endpoint of MI or target vessel revascularization at 3. Pooled Analysis of DEFINE-FLAIR and iFR-SWEDEHEART myocardial territories remote to those subtended by nonculprit stenoses (25) . We explored whether iFR or 
